A Quantitative Framework to Identify and Prioritize Opportunities in Biomedical Product Innovation
Open Access
- 5 May 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 4 (5) , e230894
Abstract
Prioritization and funding for health initiatives, including biomedical innovation, may not consistently target unmet public health needs. Public health leaders and industry funders who rely on select metrics like mortality to inform strategic priorities and funding decisions can potentially overlook important considerations, including the effects of disability, cost of treatment, and health disparities. Furthermore, medical research priorities are frequently determined by expert consensus or stakeholder ranking1,2 and can be influenced by advocacy for or bias against select medical disorders.3 A quantitative framework with comprehensive metrics that leverages latest or currently available data across the health ecosystem can help identify, track, prioritize, and align opportunities in biomedical product innovation to address unmet health needs in communities.4,5Keywords
This publication has 20 references indexed in Scilit:
- New indicators and indexes for benchmarking university–industry–government innovation in medical and life science clusters: results from the European FP7 Regions of Knowledge HealthTIES projectHealth Research Policy and Systems, 2019
- The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of DrugsHealth Affairs, 2019
- Priority-setting in public health research funding organisations: an exploratory qualitative study among five high-profile fundersHealth Research Policy and Systems, 2018
- A dynamic map for learning, communicating, navigating and improving therapeutic developmentNature Reviews Drug Discovery, 2017
- Approaches, tools and methods used for setting priorities in health research in the 21st centuryJournal of Global Health, 2015
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- How Are Health Research Priorities Set in Low and Middle Income Countries? A Systematic Review of Published ReportsPLOS ONE, 2014
- An End to the Myth: There Is No Drug Development PipelineScience Translational Medicine, 2013
- A comparison of cancer burden and research spending reveals discrepancies in the distribution of research fundingBMC Public Health, 2012
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsClinical Pharmacology & Therapeutics, 2010